imidafenacin    B-Imidazole114916670
(    O
INN    O
)    O

Carbimazole    B-Imidazole114916670
is    O
used    O
to    O
treat    O
hyperthyroidism    O
.    O

The    O
main    O
antithyroid    O
drugs    O
are    O
carbimazole    B-Imidazole114916670
(    O
in    O
the    O
UK    O
)    O
,    O
methimazole    O
(    O
in    O
the    O
US    O
)    O
,    O
and    O
propylthiouracil    O
/    O
PTU    O
.    O

Imafen    B-Imidazole114916670
(    O
R25540    B-Imidazole114916670
)    O
is    O
an    O
antidepressant    O
which    O
was    O
patented    O
in    O
the    O
mid    O
1970s    O
by    O
Janssen    O
,    O
but    O
was    O
never    O
marketed    O
.    O

Rifaximin    B-Imidazole114916670
,    O
sold    O
under    O
the    O
trade    O
name    O
Xifaxan    B-Imidazole114916670
among    O
others    O
,    O
is    O
an    O
antibiotic    O
used    O
to    O
treat    O
traveler    O
's    O
diarrhea    O
,    O
irritable    O
bowel    O
syndrome    O
,    O
and    O
hepatic    O
encephalopathy    O
.    O

Rifaximin    B-Imidazole114916670
may    O
also    O
be    O
useful    O
.    O

Rifaximin    B-Imidazole114916670
is    O
approved    O
in    O
the    O
U.S.    O
for    O
treatment    O
of    O
TD    O
caused    O
by    O
ETEC    O
.    O

Hexaarylbiimidazole    B-Imidazole114916670
(    O
HABI    O
)    O
is    O
an    O
organic    O
compound    O
and    O
an    O
imidazole    O
derivative    O
.    O

Certain    O
medications    O
,    O
e.g.    O
amiodarone    O
,    O
bleomycin    B-Imidazole114916670
(    O
pingyangmycin    B-Imidazole114916670
)    O
,    O
busulfan    O
,    O
methotrexate    O
,    O
apomorphine    O
,    O
and    O
nitrofurantoin    O

Yeast    O
infections    O
in    O
the    O
vagina    O
,    O
caused    O
by    O
"    O
Candida    O
albicans    O
"    O
,    O
can    O
be    O
treated    O
with    O
medicated    O
suppositories    O
such    O
as    O
tioconazole    B-Imidazole114916670
and    O
pessaries    O
whereas    O
skin    O
yeast    O
infections    O
are    O
treated    O
with    O
medicated    O
ointments    O
.    O

tioconazole    B-Imidazole114916670
(    O
antifungal    O
)    O

Zoledronate    B-Imidazole114916670
(    O
Zometa    O
,    O
Aclasta    B-Imidazole114916670
)    O
—    O
10000    O

Of    O
pharmacological    O
interest    O
and    O
with    O
bioactivities    O
comparable    O
to    O
that    O
of    O
IPP    O
are    O
synthetic    O
aminobisphosphonates    O
such    O
as    O
zoledronate    B-Imidazole114916670
(    O
Zometa    O
)    O
or    O
pamidronate    O
(    O
Aredia    O
)    O
,    O
that    O
are    O
widely    O
used    O
to    O
treat    O
osteoporosis    O
and    O
bone    O
metastases    O
,    O
and    O
incidentally    O
act    O
as    O
Vγ9/Vδ2    O
T    O
cell    O
receptor    O
agonists    O
.    O

Etidronate    O
has    O
the    O
same    O
disadvantage    O
as    O
pyrophosphate    O
in    O
inhibiting    O
mineralization    O
,    O
but    O
all    O
of    O
the    O
potent    O
"    O
N    O
"-    O
containing    O
bisphosphonates    O
including    O
Alendronate    O
and    O
also    O
risedronate    O
,    O
ibandronate    O
,    O
and    O
zoledronate    B-Imidazole114916670
,    O
do    O
not    O
.    O

IPSC    O
treatment    O
with    O
SB-431542    B-Imidazole114916670
leads    O
to    O
rapid    O
and    O
uniform    O
MSC    O
generation    O
from    O
human    O
iPSCs    O
.    O

Unlike    O
thromboxane    O
synthase    O
inhibitors    O
such    O
as    O
ozagrel    B-Imidazole114916670
,    O
seratrodast    O
does    O
not    O
affect    O
thrombus    O
formation    O
,    O
time    O
to    O
occlusion    O
and    O
bleeding    O
time    O
.    O

Ageliferin    B-Imidazole114916670

cenicriviroc    B-Imidazole114916670
(    O
USAN    O
)    O
,    O
INN    O
)    O

The    O
stable    O
oxadiazoles    O
appear    O
in    O
a    O
variety    O
of    O
pharmaceutical    O
drugs    O
including    O
raltegravir    O
,    O
butalamine    O
,    O
fasiplon    O
,    O
oxolamine    O
,    O
and    O
pleconaril    B-Imidazole114916670
.    O

The    O
anti    O
-    O
viral    O
drug    O
pleconaril    B-Imidazole114916670
interferes    O
with    O
the    O
binding    O
of    O
the    O
echovirus    O
particle    O
to    O
the    O
cell    O
membrane    O
and    O
the    O
drug    O
also    O
hinders    O
the    O
uncoating    O
of    O
virions    O
by    O
attaching    O
itself    O
to    O
the    O
viral    O
protein    O
capsid    O
.    O

It    O
contains    O
amlodipine    O
,    O
a    O
calcium    O
channel    O
blocker    O
,    O
and    O
olmesartan    B-Imidazole114916670
medoxomil    I-Imidazole114916670
(    O
trade    O
name    O
:    O
Benicar    O
)    O
,    O
an    O
angiotensin-2    O
receptor    O
antagonist    O
(    O
ARB    O
or    O
A2A    O
)    O
.    O

olmesartan    B-Imidazole114916670

In    O
a    O
study    O
of    O
108    O
patients    O
with    O
early    O
morning    O
blood    O
pressure    O
more    O
than    O
135/85    O
mmHg    O
,    O
Candesartan    O
showed    O
significantly    O
early    O
morning    O
Blood    O
Pressure    O
decreased    O
over    O
amlodipine    O
,    O
and    O
also    O
to    O
ARBs    O
,    O
valsartan    O
,    O
losartan    O
,    O
telmisartan    O
,    O
but    O
not    O
olmesartan    B-Imidazole114916670
.    O

Redirects    O
to    O
"    O
clotrimazole    B-Imidazole114916670
"    O
.    O

Redirects    O
to    O
"    O
clotrimazole    B-Imidazole114916670
"    O
.    O

Lotrimin    B-Imidazole114916670

Lanosterol    O
14α-demethylase    O
(    O
CYP51A1    O
)    O
inhibitors    O
such    O
as    O
clotrimazole    B-Imidazole114916670
,    O
fluconazole    O
,    O
itraconazole    O
,    O
ketoconazole    B-Imidazole114916670
,    O
miconazole    O
,    O
and    O
voriconazole    O
prevent    O
the    O
production    O
of    O
ergosterol    O
from    O
lanosterol    O
.    O

Combined    O
with    O
marbofloxacin    O
and    O
clotrimazole    B-Imidazole114916670
,    O
dexamethasone    O
is    O
available    O
under    O
the    O
name    O
Aurizon    O
,    O
CAS    O
number    O
115550    O
-    O
35    O
-    O
1    O
,    O
and    O
used    O
to    O
treat    O
difficult    O
ear    O
infections    O
,    O
especially    O
in    O
dogs    O
.    O

Treatment    O
is    O
typically    O
with    O
antifungal    O
creams    O
such    O
as    O
clotrimazole    B-Imidazole114916670
or    O
miconazole    O
.    O

Antifungal    O
treatments    O
include    O
topical    O
agents    O
such    O
as    O
miconazole    O
,    O
terbinafine    O
,    O
clotrimazole    B-Imidazole114916670
,    O
ketoconazole    B-Imidazole114916670
,    O
or    O
tolnaftate    O
applied    O
twice    O
daily    O
until    O
symptoms    O
resolve    O
—    O
usually    O
within    O
one    O
or    O
two    O
weeks    O
.    O

clotrimazole    B-Imidazole114916670
(    O
antifungal    O
)    O

Coumermycin    B-Imidazole114916670
A1    I-Imidazole114916670
is    O
an    O
aminocoumarin    O
.    O

Imetit    B-Imidazole114916670
is    O
a    O
histamine    O
H3    O
receptor    O
agonist    O
.    O

eprosartan    B-Imidazole114916670
(    O
INN    O
)    O

Eprosartan    B-Imidazole114916670

Impromidine    B-Imidazole114916670
(    O
INN    O
)    O
is    O
a    O
highly    O
potent    O
and    O
specific    O
histamine    O
H2    O
receptor    O
agonist    O
.    O

:    O
D01AC10    O
Bifonazole    B-Imidazole114916670

ABT-239    O
is    O
more    O
active    O
at    O
the    O
human    O
H3    O
receptor    O
than    O
comparable    O
agents    O
such    O
as    O
thioperamide    O
,    O
ciproxifan    B-Imidazole114916670
,    O
and    O
cipralisant    B-Imidazole114916670
.    O

Avapro    O
(    O
irbesartan    B-Imidazole114916670
)    O
—    O
comarketed    O
with    O
Sanofi    O

irbesartan    B-Imidazole114916670

Irbesartan    B-Imidazole114916670

abunidazole    B-Imidazole114916670
(    O
INN    O
)    O

Co    O
-    O
administration    O
of    O
atorvastatin    O
with    O
one    O
of    O
CYP3A4    O
inhibitors    O
such    O
as    O
itraconazole    O
,    O
telithromycin    B-Imidazole114916670
,    O
and    O
voriconazole    O
,    O
may    O
increase    O
serum    O
concentrations    O
of    O
atorvastatin    O
,    O
which    O
may    O
lead    O
to    O
adverse    O
reactions    O
.    O

Ketek    B-Imidazole114916670
(    O
Sanofi    O
-    O
Aventis    O
)    O
redirects    O
to    O
"    O
telithromycin    B-Imidazole114916670
"    O

Caution    O
should    O
be    O
exercised    O
when    O
aliskiren    O
is    O
administered    O
with    O
ketoconazole    O
or    O
other    O
moderate    O
P    O
-    O
glycoprotein    O
inhibitors    O
(    O
itraconazole    O
,    O
clarithromycin    O
,    O
telithromycin    B-Imidazole114916670
,    O
erythromycin    O
,    O
or    O
amiodarone    O
)    O
.    O

:    O
N06BX10    O
Nizofenone    B-Imidazole114916670

Note    O
that    O
two    O
natural    O
products    O
were    O
already    O
known    O
with    O
this    O
imidazole    O
riboside    O
structure    O
:    O
substitution    O
at    O
the    O
5    O
'    O
carbon    O
with    O
OH    O
results    O
in    O
pyrazomycin    O
/    O
pyrazofurin    O
,    O
an    O
antibiotic    O
with    O
antiviral    O
properties    O
but    O
unacceptable    O
toxicity    O
,    O
and    O
replacement    O
with    O
an    O
amino    O
group    O
results    O
in    O
the    O
natural    O
purine    O
synthetic    O
precursor    O
5-aminoimidazole-4-carboxamide-1-β-D    O
-    O
ribofuranoside    O
(    O
AICAR    B-Imidazole114916670
)    O
,    O
which    O
has    O
only    O
modest    O
antiviral    O
properties    O
.    O

Proxyfan    B-Imidazole114916670
is    O
a    O
histamine    O
H3    O
receptor    O
ligand    O
which    O
is    O
a    O
"    O
protean    O
agonist    O
"    O
,    O
producing    O
different    O
effects    O
ranging    O
from    O
full    O
agonist    O
,    O
to    O
antagonist    O
,    O
to    O
inverse    O
agonist    O
in    O
different    O
tissues    O
,    O
depending    O
on    O
the    O
level    O
of    O
constitutive    O
activity    O
of    O
the    O
histamine    O
H3    O
receptor    O
.    O

4-NEMD    B-Imidazole114916670

Adipiplon    B-Imidazole114916670

4-Methylhistamine    B-Imidazole114916670

Tipifarnib    B-Imidazole114916670
(    O
INN    O
,    O
proposed    O
trade    O
name    O
Zarnestra    B-Imidazole114916670
)    O
is    O
a    O
farnesyltransferase    O
inhibitor    O
that    O
is    O
being    O
investigated    O
in    O
patients    O
65    O
years    O
of    O
age    O
and    O
older    O
with    O
newly    O
diagnosed    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
.    O

While    O
PTC124    B-Imidazole114916670
showed    O
promising    O
results    O
in    O
mice    O
,    O
the    O
Phase    O
II    O
trial    O
was    O
suspended    O
when    O
participants    O
did    O
not    O
show    O
significant    O
increases    O
in    O
the    O
six    O
-    O
minute    O
walk    O
distance    O
.    O

Ataluren    B-Imidazole114916670
,    O
targeting    O
premature    O
stop    O
codons    O

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    O
,    O
brotizolam    B-Imidazole114916670
,    O
flunitrazepam    O
,    O
loprazolam    O
,    O
lorazepam    O
,    O
lormetazepam    O
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O

Brotizolam    B-Imidazole114916670

Zolpidem    B-Imidazole114916670
(    O
Ambien    O
)    O
is    O
one    O
of    O
the    O
most    O
common    O
date    O
-    O
rape    O
drugs    O
according    O
to    O
the    O
U.S.    O
Drug    O
Enforcement    O
Administration    O
.    O

Eminem    O
has    O
spoken    O
publicly    O
about    O
his    O
addiction    O
to    O
prescription    O
drugs    O
,    O
including    O
Vicodin    O
,    O
Ambien    B-Imidazole114916670
and    O
Valium    O
.    O

#    O
Zolpidem    B-Imidazole114916670

Middle    O
-    O
of    O
-    O
the    O
-    O
night    O
insomnia    O
is    O
often    O
treated    O
with    O
medication    O
,    O
although    O
currently    O
Intermezzo    O
(    O
zolpidem    B-Imidazole114916670
tartrate    O
sublingual    O
tablets    O
)    O
is    O
the    O
only    O
Food    O
and    O
Drug    O
Administration    O
-    O
approved    O
medication    O
specifically    O
for    O
treating    O
MOTN    O
awakening    O
.    O

Seau    O
had    O
insomnia    O
for    O
at    O
least    O
the    O
last    O
seven    O
years    O
of    O
his    O
life    O
,    O
and    O
he    O
was    O
taking    O
zolpidem    B-Imidazole114916670
(    O
Ambien    O
)    O
,    O
a    O
prescription    O
drug    O
commonly    O
prescribed    O
for    O
sleep    O
disorders    O
.    O

The    O
potential    O
for    O
psychological    O
dependence    O
is    O
similar    O
to    O
that    O
of    O
zolpidem    B-Imidazole114916670
.    O

According    O
to    O
the    O
U.S.    O
Drug    O
Enforcement    O
Administration    O
(    O
DEA    O
)    O
,    O
suvorexant    O
produces    O
similar    O
reinforcing    O
effects    O
to    O
those    O
of    O
zolpidem    B-Imidazole114916670
in    O
humans    O
and    O
thus    O
may    O
have    O
a    O
similar    O
abuse    O
liability    O
.    O

Cosentino    O
wrote    O
"    O
Fear    O
of    O
My    O
Identity    O
"    O
about    O
"    O
having    O
an    O
existential    O
crisis    O
"    O
after    O
using    O
the    O
sedative    O
Ambien    B-Imidazole114916670
.    O

Zolpidem    B-Imidazole114916670
Tartrate    I-Imidazole114916670
,    O
a    O
popular    O
prescription    O
sleep    O
medication    O
commonly    O
known    O
by    O
the    O
brand    O
name    O
Ambien    O

zolpidem    B-Imidazole114916670
(    O
z    O
-    O
drug    O
)    O

Zolpidem    B-Imidazole114916670
(    O
Ambien    O
,    O
Stilnox    O
)    O

Many    O
drivers    O
had    O
blood    O
levels    O
far    O
exceeding    O
the    O
therapeutic    O
dose    O
range    O
,    O
suggesting    O
a    O
high    O
degree    O
of    O
abuse    O
potential    O
for    O
benzodiazepines    O
and    O
zolpidem    B-Imidazole114916670
and    O
zopiclone    O
.    O

During    O
the    O
23    O
years    O
at    O
Synthelabo    O
,    O
Dr.    O
Langer    O
discovered    O
and    O
developed    O
five    O
compounds    O
:    O
diltiazem    O
,    O
a    O
calcium    O
antagonist    O
(    O
for    O
coronary    O
insufficiency    O
)    O
;    O
betazolol    O
,    O
a    O
beta-1    O
adrenoceptor    O
selective    O
antagonist    O
for    O
hypertension    O
and    O
also    O
for    O
local    O
use    O
in    O
the    O
treatment    O
of    O
glaucoma    O
;    O
zolpidem    B-Imidazole114916670
,    O
a    O
selective    O
full    O
agonist    O
of    O
the    O
alpha-1    O
subunit    O
of    O
the    O
benzodiazepine    O
-    O
GABA    O
-    O
A    O
receptor    O
(    O
for    O
insomnia    O
)    O
and    O
mizolastine    O
,    O
a    O
peripherally    O
acting    O
histamine    O
H-1    O
receptor    O
antagonist    O
which    O
also    O
inhibits    O
the    O
formation    O
of    O
leukotriens(for    O
allergic    O
diseases    O
)    O
.    O

This    O
has    O
also    O
been    O
recorded    O
in    O
non    O
-    O
benzodiazapine    O
sedatives    O
or    O
"    O
z    O
-    O
drugs    O
"    O
which    O
act    O
on    O
the    O
same    O
set    O
of    O
receptors    O
;    O
such    O
as    O
zolpidem    B-Imidazole114916670
(    O
also    O
known    O
as    O
Ambien    O
)    O
,    O
eszopiclone    O
(    O
also    O
known    O
as    O
Lunesta    O
)    O
,    O
and    O
zopiclone    O
(    O
also    O
known    O
by    O
brand    O
names    O
Imovane    O
and    O
Zimovane    O
)    O
.    O

It    O
can    O
also    O
be    O
a    O
side    O
effect    O
of    O
benzodiazepines    O
or    O
opioids    O
,    O
particularly    O
if    O
used    O
in    O
larger    O
doses    O
for    O
recreation    O
,    O
the    O
anti    O
-    O
epileptic    O
drugs    O
Phenytoin    O
and    O
Zonisamide    O
,    O
and    O
the    O
anti    O
-    O
convulsant    O
drug    O
Lamotrigine    O
,    O
as    O
well    O
as    O
the    O
hypnotic    O
drug    O
Zolpidem    B-Imidazole114916670
and    O
the    O
dissociative    O
drugs    O
Ketamine    O
and    O
Dextromethorphan    O
.    O

The    O
sleep    O
latency    O
improvement    O
at    O
the    O
100    O
mg    O
dose    O
is    O
comparable    O
to    O
FDA    O
approved    O
zolpidem    B-Imidazole114916670
's    O
effects    O
.    O

Melanotan    B-Imidazole114916670
II    I-Imidazole114916670

Melanotan    B-Imidazole114916670
II    I-Imidazole114916670

Melanotan    B-Imidazole114916670
II    I-Imidazole114916670

Stimulatory    O
factor    O
:    O
bombesin    B-Imidazole114916670
or    O
gastrin    O
-    O
releasing    O
peptide    O
(    O
GRP    O
)    O

Neuromedin    O
B    O
(    O
NMB    O
)    O
is    O
a    O
bombesin    B-Imidazole114916670
-    O
related    O
peptide    O
in    O
mammals    O
.    O

In    O
some    O
types    O
of    O
cancer    O
,    O
such    O
as    O
metastatic    O
carcinoma    O
and    O
some    O
advanced    O
melanomas    O
,    O
neprilysin    O
is    O
overexpressed    O
;    O
in    O
other    O
types    O
,    O
most    O
notably    O
lung    O
cancers    O
,    O
neprilysin    O
is    O
downregulated    O
,    O
and    O
thus    O
unable    O
to    O
modulate    O
the    O
pro    O
-    O
growth    O
autocrine    O
signaling    O
of    O
cancer    O
cells    O
via    O
secreted    O
peptides    O
such    O
as    O
mammalian    O
homologs    O
related    O
to    O
bombesin    B-Imidazole114916670
.    O

It    O
arises    O
via    O
the    O
action    O
of    O
urocanase    O
on    O
urocanic    B-Imidazole114916670
acid    I-Imidazole114916670
.    O

Urocanate    B-Imidazole114916670

Sertaconazole    B-Imidazole114916670
(    O
Ertaczo,    B-Imidazole114916670
Dermofix,    I-Imidazole114916670
Konzert,    I-Imidazole114916670
Zalain    I-Imidazole114916670
)    O
is    O
an    O
antifungal    O
medication    O
of    O
the    O
imidazole    O
class    O
.    O

Streptomyces    O
netropsis    O
"    O
produces    O
the    O
antibiotics    O
netropsin    B-Imidazole114916670
and    O
distamycin    O
A    O
and    O
the    O
antifungal    O
antibiotic    O
mycoheptin    O
.    O

They    O
are    O
structural    O
analogs    O
of    O
the    O
natural    O
antibiotics    O
netropsin    B-Imidazole114916670
and    O
distamycin    O
.    O

Liarozole    B-Imidazole114916670
is    O
a    O
retinoic    O
acid    O
metabolism    O
-    O
blocking    O
drug    O
and    O
aromatase    O
inhibitor    O
.    O

Methimepip    B-Imidazole114916670
is    O
a    O
histamine    O
agonist    O
which    O
is    O
highly    O
selective    O
for    O
the    O
H3    O
subtype    O
.    O

:    O
G01AF12    O
Fenticonazole    B-Imidazole114916670

:    O
G01AF17    O
Oxiconazole    B-Imidazole114916670

ramosetron    B-Imidazole114916670
(    O
INN    O
)    O

Immepip    B-Imidazole114916670
is    O
a    O
histamine    O
H3    O
receptor    O
agonist    O
.    O

croconazole    B-Imidazole114916670
(    O
INN    O
)    O

This    O
suggests    O
that    O
NS5A    O
inhibitors    O
act    O
on    O
dimers    O
of    O
NS5A.    O
A    O
number    O
of    O
modeling    O
studies    O
have    O
shown    O
that    O
daclatasvir    B-Imidazole114916670
,    O
which    O
is    O
an    O
NS5A    O
inhibitor    O
,    O
only    O
binds    O
to    O
the    O
"    O
back    O
-    O
to    O
-    O
back    O
"    O
NS5A    O
dimer    O
and    O
that    O
the    O
binding    O
has    O
to    O
be    O
symmetrical    O
.    O

Daclatasvir    B-Imidazole114916670
was    O
the    O
first    O
clinically    O
approved    O
NS5A    O
inhibitor    O
.    O

Alosetron    B-Imidazole114916670

Alosetron    B-Imidazole114916670

Most    O
doctors    O
use    O
the    O
plasma    O
concentrations    O
of    O
the    O
waste    O
substances    O
of    O
creatinine    B-Imidazole114916670
and    O
urea    O
(    O
U    O
)    O
,    O
as    O
well    O
as    O
electrolytes    O
(    O
E    O
)    O
,    O
to    O
determine    O
renal    O
function    O
.    O

However    O
,    O
blood    O
urea    O
nitrogen    O
(    O
BUN    O
)    O
and    O
creatinine    B-Imidazole114916670
will    O
not    O
be    O
raised    O
above    O
the    O
normal    O
range    O
until    O
60%    O
of    O
total    O
kidney    O
function    O
is    O
lost    O
.    O

Creatinine    O
is    O
produced    O
naturally    O
by    O
the    O
body    O
(    O
creatinine    B-Imidazole114916670
is    O
a    O
breakdown    O
product    O
of    O
creatine    O
phosphate    O
,    O
which    O
is    O
found    O
in    O
muscle    O
)    O
.    O

A    O
commonly    O
used    O
surrogate    O
marker    O
for    O
estimate    O
of    O
creatinine    O
clearance    O
is    O
the    O
Cockcroft    O
-    O
Gault    O
(    O
CG    O
)    O
formula    O
,    O
which    O
in    O
turn    O
estimates    O
GFR    O
in    O
ml    O
/    O
min    O
:    O
It    O
is    O
named    O
after    O
the    O
scientists    O
,    O
the    O
asthmologist    O
(    O
b.    O
1946    O
)    O
and    O
the    O
nephrologist    O
Matthew    O
Henry    O
Gault    O
(    O
1925–2003    O
)    O
,    O
who    O
first    O
published    O
the    O
formula    O
in    O
1976    O
,    O
and    O
it    O
employs    O
serum    O
creatinine    B-Imidazole114916670
measurements    O
and    O
a    O
patient    O
's    O
weight    O
to    O
predict    O
the    O
creatinine    O
clearance    O
.    O

Infrequent    O
ADRs    O
include    O
:    O
dyslipidemia    O
,    O
increased    O
serum    O
creatinine    B-Imidazole114916670
concentration    O
,    O
hypocalcemia    O
,    O
rash    O
.    O

While    O
"    O
shocking    O
"    O
pools    O
to    O
reduce    O
the    O
buildup    O
of    O
chloramines    O
works    O
with    O
inorganic    O
,    O
ammonia    O
-    O
based    O
chloramines    O
,    O
in    O
two    O
studies    O
it    O
was    O
found    O
ineffective    O
with    O
the    O
organic    O
chloramines    O
present    O
in    O
all    O
pool    O
water    O
eg    O
with    O
creatinine    B-Imidazole114916670
,    O
an    O
organic    O
component    O
in    O
human    O
sweat    O
.    O

ECD    O
donors    O
are    O
normally    O
aged    O
60    O
years    O
or    O
older    O
,    O
or    O
over    O
50    O
years    O
with    O
at    O
least    O
two    O
of    O
the    O
following    O
conditions    O
:    O
hypertension    O
history    O
,    O
serum    O
creatinine    B-Imidazole114916670
>    O
1.5    O
mg    O
/    O
dl    O
or    O
cause    O
of    O
death    O
from    O
cerebrovascular    O
accident    O
.    O

In    O
solution    O
,    O
creatine    O
is    O
in    O
equilibrium    O
with    O
creatinine    B-Imidazole114916670
.    O

The    O
most    O
prevalent    O
of    O
these    O
contaminants    O
was    O
creatinine    B-Imidazole114916670
,    O
a    O
breakdown    O
product    O
of    O
creatine    O
also    O
produced    O
by    O
the    O
body    O
.    O

Creatinine    B-Imidazole114916670
was    O
present    O
in    O
higher    O
concentrations    O
than    O
the    O
European    O
Food    O
Safety    O
Authority    O
recommendations    O
in    O
44%    O
of    O
the    O
samples    O
.    O

levels    O
of    O
creatinine    B-Imidazole114916670
in    O
the    O
blood    O
.    O

Male    O
heterozygotes    O
displayed    O
increased    O
circulating    O
creatinine    B-Imidazole114916670
levels    O
and    O
an    O
increased    O
susceptibility    O
to    O
"    O
Salmonella    O
"    O
infection    O
.    O

Can    O
compete    O
with    O
creatinine    B-Imidazole114916670
for    O
secretion    O
into    O
the    O
renal    O
tubule    O
.    O

|rowspan=4|    O
Creatinine    B-Imidazole114916670

Creatinine    B-Imidazole114916670
:    O
0.18(0.061    O
)    O

A    O
simple    O
means    O
of    O
estimating    O
renal    O
function    O
is    O
to    O
measure    O
pH    O
,    O
blood    O
urea    O
nitrogen    O
,    O
creatinine    B-Imidazole114916670
,    O
and    O
basic    O
electrolytes    O
(    O
including    O
sodium    O
,    O
potassium    O
,    O
chloride    O
,    O
and    O
bicarbonate    O
)    O
.    O

The    O
most    O
common    O
adverse    O
reactions    O
(    O
≥30%    O
occurrence    O
,    O
leading    O
to    O
a    O
5%    O
treatment    O
discontinuation    O
rate    O
)    O
observed    O
with    O
sirolimus    O
in    O
clinical    O
studies    O
of    O
organ    O
rejection    O
prophylaxis    O
in    O
individuals    O
with    O
kidney    O
transplants    O
include    O
:    O
peripheral    O
edema    O
,    O
hypercholesterolemia    O
,    O
abdominal    O
pain    O
,    O
headache    O
,    O
nausea    O
,    O
diarrhea    O
,    O
pain    O
,    O
constipation    O
,    O
hypertriglyceridemia    O
,    O
hypertension    O
,    O
increased    O
creatinine    B-Imidazole114916670
,    O
fever    O
,    O
urinary    O
tract    O
infection    O
,    O
anemia    O
,    O
arthralgia    O
,    O
and    O
thrombocytopenia    O
.    O

Substances    O
secreted    O
include    O
urea    O
,    O
creatinine    B-Imidazole114916670
,    O
potassium    O
,    O
hydrogen    O
,    O
and    O
uric    O
acid    O
.    O

MELD    O
uses    O
the    O
patient    O
's    O
values    O
for    O
serum    O
bilirubin    O
,    O
serum    O
creatinine    B-Imidazole114916670
,    O
and    O
the    O
international    O
normalized    O
ratio    O
for    O
prothrombin    O
time    O
(    O
INR    O
)    O
to    O
predict    O
survival    O
.    O

Some    O
less    O
frequently    O
reported    O
adverse    O
events    O
(    O
incidence    O
<    O
1%    O
)    O
include    O
phlebitis    O
,    O
itchiness    O
,    O
fever    O
,    O
chills    O
,    O
nausea    O
,    O
vomiting    O
,    O
elevations    O
of    O
bilirubin    O
,    O
elevations    O
in    O
creatinine    B-Imidazole114916670
,    O
headache    O
and    O
dizziness    O
.    O

creatinine    B-Imidazole114916670

In    O
addition    O
to    O
vasodilation    O
,    O
the    O
effects    O
of    O
relaxin    O
are    O
also    O
seen    O
in    O
the    O
kidneys    O
,    O
by    O
significantly    O
increasing    O
creatinine    B-Imidazole114916670
clearance    O
,    O
which    O
is    O
a    O
measure    O
of    O
kidney    O
function    O
,    O
as    O
well    O
as    O
increased    O
renal    O
blood    O
flow    O
.    O

A    O
blood    O
test    O
may    O
reveal    O
increases    O
in    O
blood    O
urea    O
nitrogen    O
(    O
BUN    O
)    O
,    O
creatinine    B-Imidazole114916670
,    O
phosphorus    O
,    O
and    O
calcium    O
.    O

Clorobiocin    B-Imidazole114916670
is    O
an    O
aminocoumarin    O
.    O

Pulmonary    O
toxicity    O
,    O
or    O
lung    O
damage    O
,    O
can    O
occur    O
with    O
the    O
use    O
of    O
bleomycin    B-Imidazole114916670
in    O
ABVD    O
,    O
especially    O
when    O
radiation    O
therapy    O
to    O
the    O
chest    O
is    O
also    O
given    O
as    O
part    O
of    O
the    O
treatment    O
for    O
Hodgkin    O
's    O
lymphoma    O
.    O

Streptomyces    O
mobaraensis    O
"    O
produces    O
bleomycin    B-Imidazole114916670
,    O
detoxin    O
,    O
piericidin    O
A    O
,    O
piericidin    O
B    O
,    O
reticulol    O
and    O
transglutaminase    O
.    O

Exposure    O
to    O
certain    O
chemicals    O
such    O
as    O
salicylic    O
acid    O
,    O
bleomycin    B-Imidazole114916670
,    O
and    O
cisplatin    O
.    O

Chemicals    O
such    O
as    O
bleomycin    B-Imidazole114916670
,    O
tetracycline    O
(    O
e.g.    O
,    O
minocycline    O
)    O
,    O
povidone    O
-    O
iodine    O
,    O
or    O
a    O
slurry    O
of    O
talc    O
can    O
be    O
introduced    O
into    O
the    O
pleural    O
space    O
through    O
a    O
chest    O
drain    O
.    O

For    O
example    O
,    O
glyoxalase    O
I    O
resembles    O
several    O
proteins    O
that    O
allow    O
bacteria    O
to    O
resist    O
antibiotics    O
such    O
as    O
fosfomycin    O
,    O
bleomycin    B-Imidazole114916670
and    O
mitomycin    O
.    O

Phleomycins    O
are    O
a    O
group    O
of    O
glycopeptide    O
antibiotics    O
found    O
in    O
"    O
Streptomycin    O
"    O
which    O
are    O
closely    O
related    O
to    O
bleomycin    B-Imidazole114916670
.    O

EP2    O
expression    O
in    O
fibroblasts    O
from    O
the    O
lungs    O
of    O
mice    O
with    O
Bleomycin    B-Imidazole114916670
-    O
induced    O
pulmonary    O
fibrosis    O
and    O
humans    O
with    O
Idiopathic    O
pulmonary    O
fibrosis    O
is    O
greatly    O
reduced    O
.    O

"    O
PTGFR    O
"    O
knockout    O
mice    O
also    O
show    O
a    O
reduction    O
in    O
the    O
development    O
of    O
pulmonary    O
fibrosis    O
normally    O
caused    O
by    O
microbial    O
invasion    O
or    O
bleomycin    B-Imidazole114916670
treatment    O
.    O

On    O
the    O
other    O
hand    O
,    O
IP    O
receptors    O
may    O
serve    O
to    O
promote    O
non    O
-    O
allergic    O
inflammatory    O
responses    O
:    O
IP    O
receptor    O
-    O
deficient    O
mice    O
exhibited    O
increased    O
lung    O
inflammation    O
in    O
a    O
model    O
of    O
bleomycin    B-Imidazole114916670
-    O
induced    O
pulmonary    O
fibrosis    O
while    O
mice    O
made    O
to    O
over    O
-    O
express    O
the    O
PGI2-forming    O
enzyme    O
,    O
Prostacyclin    O
synthase    O
,    O
in    O
their    O
airway    O
epithelial    O
cells    O
were    O
protected    O
against    O
lung    O
injury    O
in    O
this    O
model    O
.    O

Certain    O
drugs    O
such    O
as    O
amiodarone    O
,    O
bleomycin    B-Imidazole114916670
and    O
methotrexate    O
.    O

Exposure    O
of    O
"    O
Sulfolobus    O
solfataricus    O
"    O
to    O
the    O
DNA    O
damaging    O
agents    O
UV    O
-    O
irradiation    O
,    O
bleomycin    B-Imidazole114916670
or    O
mitomycin    O
C    O
induces    O
cellular    O
aggregation    O
.    O

Neticonazole    B-Imidazole114916670
(    O
INN    O
)    O
is    O
an    O
imidazole    O
antifungal    O
for    O
the    O
treatment    O
of    O
fungal    O
skin    O
infections    O
.    O

The    O
azo    O
-    O
transfer    O
compounds    O
,    O
trifluoromethanesulfonyl    O
azide    O
and    O
imidazole-1-sulfonyl    B-Imidazole114916670
azide    I-Imidazole114916670
,    O
are    O
prepared    O
from    O
sodium    O
azide    O
as    O
well    O
.    O

azalanstat    B-Imidazole114916670
(    O
INN    O
)    O

Propoxate    O
(    O
INN    O
;    O
R7464    O
)    O
is    O
an    O
anesthetic    O
related    O
to    O
etomidate    B-Imidazole114916670
and    O
metomidate    B-Imidazole114916670
that    O
was    O
never    O
marketed    O
.    O

Radotinib    B-Imidazole114916670
(    O
INN    O
;    O
trade    O
name    O
Supect    B-Imidazole114916670
)    O
,    O
and    O
sometimes    O
referred    O
to    O
by    O
its    O
investigational    O
name    O
IY5511    B-Imidazole114916670
,    O
is    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
different    O
types    O
of    O
cancer    O
,    O
most    O
notably    O
Philadelphia    O
chromosome    O
-    O
positive    O
(    O
Ph+    O
)    O
chronic    O
myeloid    O
leukemia    O
(    O
CML    O
)    O
with    O
resistance    O
or    O
intolerance    O
of    O
other    O
Bcr    O
-    O
Abl    O
tyrosine    O
-    O
kinase    O
inhibitors    O
,    O
such    O
as    O
patients    O
resistant    O
or    O
intolerant    O
to    O
imatinib    O
.    O

UR-AK49    B-Imidazole114916670

He    O
introduced    O
the    O
di    O
-    O
peptide    O
carnosine    B-Imidazole114916670
as    O
a    O
general    O
antiageing    O
supplement    O
to    O
the    O
lay    O
public    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
carnosine    B-Imidazole114916670
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
anserine    B-Imidazole114916670
.    O

Zinc    O
L    O
-    O
carnosine    O
(    O
"    O
beta    O
"-    O
alanyl    O
-    O
L    O
-    O
histidinato    O
zinc    O
)    O
(    O
"    O
N"-(3-aminopropionyl)-L    O
-    O
histidinato    O
zinc    O
)    O
,    O
often    O
simply    O
called    O
zinc    O
carnosine    O
,    O
and    O
also    O
known    O
as    O
polaprezinc    O
,    O
is    O
a    O
mucosal    O
protective    O
chelate    O
compound    O
of    O
zinc    O
and    O
L-carnosine    B-Imidazole114916670
.    O

NS-2664    B-Imidazole114916670

Pharmalogical    O
drugs    O
can    O
also    O
be    O
given    O
accompanying    O
a    O
transsphenoidal    O
surgery    O
including    O
the    O
following    O
:    O
pasireotide    O
,    O
temozolomide    B-Imidazole114916670
and    O
octreotide    O
.    O

Although    O
temozolomide    B-Imidazole114916670
is    O
effective    O
for    O
treating    O
recurrent    O
anaplastic    O
astrocytoma    O
,    O
its    O
role    O
as    O
an    O
adjuvant    O
to    O
radiation    O
therapy    O
has    O
not    O
been    O
fully    O
tested    O
.    O

Some    O
sources    O
explicitly    O
exclude    O
the    O
triazenes    O
(    O
dacarbazine    O
,    O
mitozolomide    O
,    O
temozolomide    B-Imidazole114916670
)    O
from    O
the    O
nonclassical    O
category    O
.    O

However    O
,    O
other    O
sources    O
list    O
dacarbazine    O
as    O
nonclassical    O
,    O
and    O
some    O
include    O
temozolomide    B-Imidazole114916670
.    O

dazoxiben    B-Imidazole114916670
(    O
INN    O
)    O

Phleomycin    B-Imidazole114916670
D1    I-Imidazole114916670
(    O
zeocin    O
)    O

This    O
is    O
demonstrated    O
by    O
the    O
fact    O
that    O
1-methylimidazole    B-Imidazole114916670
does    O
not    O
work    O
as    O
a    O
substrate    O
,    O
but    O
1-methylbenzimidazole    O
reacts    O
easily    O
.    O

For    O
example    O
,    O
β-aryl    O
carboxylic    O
acids    O
can    O
be    O
efficiently    O
converted    O
to    O
β-aryl    O
ketones    O
by    O
treatment    O
of    O
an    O
acetic    O
anhydride    O
solution    O
of    O
the    O
acid    O
with    O
catalytic    O
N-methylimidazole    B-Imidazole114916670
.    O

Aspergillus    O
brevipes    O
"    O
produces    O
roquefortine    B-Imidazole114916670
C    I-Imidazole114916670
,    O
meleagrin    B-Imidazole114916670
and    O
viriditoxin    O
.    O

Isoconazole    B-Imidazole114916670

O-2545    B-Imidazole114916670

Sceptrin    B-Imidazole114916670
is    O
a    O
bioactive    O
marine    O
isolate    O
.    O

AIR    O
+    O
CO2    O
→    O
CAIR    B-Imidazole114916670
+    O
2H+    O

The    O
electrolyte    O
was    O
made    O
of    O
3-ethyl-1-methylimidazolium    B-Imidazole114916670
chloride    I-Imidazole114916670
with    O
excess    O
aluminium    O
trichloride    O
.    O

This    O
ADP    O
-    O
ribosylation    O
involves    O
the    O
transfer    O
of    O
an    O
ADP    O
-    O
ribose    O
from    O
NAD+    O
to    O
a    O
diphthamide    B-Imidazole114916670
(    O
a    O
modified    O
histidine    O
)    O
residue    O
within    O
the    O
EF-2    O
protein    O
.    O

Diphthamide    B-Imidazole114916670
is    O
a    O
post    O
-    O
translationally    O
modified    O
histidine    O
amino    O
acid    O
found    O
in    O
archaeal    O
and    O
eukaryotic    O
elongation    O
factor    O
2    O
(    O
eEF-2    O
)    O
.    O

enilconazole    B-Imidazole114916670
(    O
INN    O
)    O

The    O
fungicide    O
enilconazole    B-Imidazole114916670
(    O
commonly    O
known    O
as    O
Imazalil    O
)    O
is    O
a    O
known    O
carcinogen    O
widely    O
used    O
to    O
grow    O
citrus    O
crops    O
.    O

Beta    O
-    O
alanine    O
structure.svg|β-alanine    O
:    O
an    O
amino    O
acid    O
produced    O
by    O
aspartate    O
1-decarboxylase    O
and    O
a    O
precursor    O
to    O
coenzyme    O
A    O
and    O
the    O
peptides    O
carnosine    B-Imidazole114916670
and    O
anserine    B-Imidazole114916670
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
carnosine    B-Imidazole114916670
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
anserine    B-Imidazole114916670
.    O

AICAR    O
+    O
fTHF    O
→    O
FAICAR    B-Imidazole114916670
+    O
THF    O

oxaline    B-Imidazole114916670
.    O

SAICAR    O
→    O
AICAR    B-Imidazole114916670
+    O
Fumarate    O

ASL    O
catalyzes    O
two    O
reactions    O
in    O
the    O
purine    O
biosynthetic    O
pathway    O
that    O
makes    O
AMP    O
;    O
ASL    O
cleaves    O
adenylosuccinate    O
into    O
AMP    O
and    O
fumarate    O
,    O
and    O
cleaves    O
SAICAR    B-Imidazole114916670
into    O
AICAR    B-Imidazole114916670
and    O
fumarate    O
.    O

ABT-239    O
is    O
more    O
active    O
at    O
the    O
human    O
H3    O
receptor    O
than    O
comparable    O
agents    O
such    O
as    O
thioperamide    O
,    O
ciproxifan    B-Imidazole114916670
,    O
and    O
cipralisant    B-Imidazole114916670
.    O

Recently    O
,    O
the    O
anti    O
-    O
dandruff    O
and    O
antimycotic    O
,    O
Climbazole    B-Imidazole114916670
,    O
was    O
detected    O
in    O
waste    O
water    O
treatment    O
drainages    O
.    O

However    O
,    O
sequential    O
small    O
molecule    O
treatment    O
of    O
the    O
muscle    O
fiber    O
with    O
myoseverin    O
,    O
reversine    O
(    O
the    O
aurora    O
B    O
kinase    O
inhibitor    O
)    O
and    O
some    O
other    O
chemicals    O
:    O
BIO    O
(    O
glycogen    O
synthase-3    O
kinase    O
inhibitor    O
)    O
,    O
lysophosphatidic    O
acid    O
(    O
pleiotropic    O
activator    O
of    O
G    O
-    O
protein    O
-    O
coupled    O
receptors    O
)    O
,    O
SB203580    B-Imidazole114916670
(    O
p38    O
MAP    O
kinase    O
inhibitor    O
)    O
,    O
or    O
SQ22536    O
(    O
adenylyl    O
cyclase    O
inhibitor    O
)    O
causes    O
the    O
formation    O
of    O
new    O
muscle    O
cell    O
types    O
as    O
well    O
as    O
other    O
cell    O
types    O
such    O
as    O
precursors    O
to    O
fat    O
,    O
bone    O
and    O
nervous    O
system    O
cells    O
.    O

fGAM    O
+    O
ATP    O
→    O
AIR    B-Imidazole114916670
+    O
ADP    O
+    O
Pi    O
+    O
H2O    O

Cefpimizole    B-Imidazole114916670
(    O
INN    O
)    O
is    O
a    O
third    O
-    O
generation    O
cephalosporin    O
antibiotic    O
.    O

ASL    O
catalyzes    O
two    O
reactions    O
in    O
the    O
purine    O
biosynthetic    O
pathway    O
that    O
makes    O
AMP    O
;    O
ASL    O
cleaves    O
adenylosuccinate    O
into    O
AMP    O
and    O
fumarate    O
,    O
and    O
cleaves    O
SAICAR    B-Imidazole114916670
into    O
AICAR    B-Imidazole114916670
and    O
fumarate    O
.    O

1,1'-Carbonyldiimidazole    B-Imidazole114916670
(    O
CDI    B-Imidazole114916670
)    O
is    O
an    O
organic    O
compound    O
with    O
the    O
molecular    O
formula    O
(    O
C3H3N2)2CO    O
.    O

:    O
G01AF16    O
Omoconazole    B-Imidazole114916670

In    O
January    O
2014    O
,    O
Consumer    O
Reports    O
magazine    O
tested    O
levels    O
of    O
the    O
chemical    O
4-methylimidazole    B-Imidazole114916670
(    O
4-MeI    O
)    O
--    O
a    O
potential    O
carcinogen    O
--    O
in    O
various    O
beverages    O
in    O
the    O
United    O
States    O
and    O
found    O
that    O
Pepsi    O
ONE    O
was    O
one    O
of    O
two    O
drinks    O
that    O
contained    O
the    O
chemical    O
in    O
excess    O
of    O
29    O
micrograms    O
per    O
can    O
or    O
bottle    O
,    O
with    O
that    O
being    O
California    O
Proposition    O
65    O
's    O
daily    O
allowed    O
amount    O
for    O
foods    O
without    O
a    O
warning    O
label    O
.    O

As    O
of    O
2016    O
,    O
several    O
antisense    O
drugs    O
have    O
been    O
approved    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
:    O
fomivirsen    B-Imidazole114916670
as    O
a    O
treatment    O
for    O
cytomegalovirus    O
retinitis    O
,    O
mipomersen    O
for    O
homozygous    O
familial    O
hypercholesterolemia    O
,    O
eteplirsen    O
for    O
Duchenne    O
muscular    O
dystrophy    O
,    O
and    O
nusinersen    O
for    O
spinal    O
muscular    O
atrophy    O
.    O

Fomivirsen    B-Imidazole114916670
(    O
marketed    O
as    O
Vitravene    O
)    O
,    O
was    O
approved    O
by    O
the    O
U.S.    O
FDA    O
in    O
Aug    O
1998    O
as    O
a    O
treatment    O
for    O
cytomegalovirus    O
retinitis    O
.    O

YM-31636    B-Imidazole114916670

taltirelin    B-Imidazole114916670
(    O
INN    O
)    O

Nafimidone    B-Imidazole114916670
is    O
an    O
anticonvulsant    O
drug    O
of    O
the    O
imidazole    O
class    O
.    O

Preparation    O
of    O
1-butyl-3-methylimidazolium    B-Imidazole114916670
hexafluorophosphate    I-Imidazole114916670
from    O
"N"-methylimidazole    B-Imidazole114916670
and    O
1-chlorobutane    O
.    O

1-butyl-3-methylimidazolium    B-Imidazole114916670
chloride    I-Imidazole114916670

Nilotinib    B-Imidazole114916670
is    O
a    O
phenylamino    O
-    O
pyrimidine    O
derivative    O
that    O
is    O
structurally    O
related    O
to    O
imatinib    O
.    O

Crystal    O
structure    O
of    O
Abl    O
kinase    O
domain    O
(    O
blue    O
)    O
in    O
complex    O
with    O
nilotinib    B-Imidazole114916670
(    O
red    O
)    O
.    O

In    O
those    O
cases    O
other    O
inhibitors    O
such    O
as    O
dasatinib    O
and    O
nilotinib    B-Imidazole114916670
can    O
be    O
used    O
.    O

The    O
most    O
commonly    O
prescribed    O
antiemetics    O
in    O
the    O
US    O
are    O
promethazine    O
,    O
metoclopramide    O
and    O
ondansetron    B-Imidazole114916670
.    O

In    O
cases    O
of    O
gastroenteritis    O
,    O
serotonin    O
antagonists    O
such    O
as    O
ondansetron    B-Imidazole114916670
were    O
found    O
to    O
suppress    O
nausea    O
and    O
vomiting    O
,    O
as    O
well    O
as    O
reduce    O
the    O
need    O
for    O
IV    O
fluid    O
resuscitation    O
.    O

Corticosteroids    O
are    O
also    O
used    O
supportively    O
to    O
prevent    O
nausea    O
,    O
often    O
in    O
combination    O
with    O
5-HT3    O
antagonists    O
(    O
"    O
e.g.    O
"    O
ondansetron    B-Imidazole114916670
)    O
.    O

Dexamethasone    O
can    O
increase    O
the    O
antiemetic    O
effect    O
of    O
5-HT3    O
receptor    O
antagonists    O
,    O
such    O
as    O
ondansetron    B-Imidazole114916670
.    O

Dexamethasone    O
and    O
ondansetron    B-Imidazole114916670
are    O
more    O
effective    O
than    O
ondansetron    O
alone    O
in    O
preventing    O
postoperative    O
nausea    O
and    O
vomiting    O
.    O

Antagonism    O
of    O
the    O
5-HT3    O
receptor    O
,    O
an    O
action    O
mirtazapine    O
shares    O
with    O
the    O
approved    O
antiemetic    O
ondansetron    B-Imidazole114916670
,    O
significantly    O
improves    O
pre    O
-    O
existing    O
symptoms    O
of    O
nausea    O
,    O
vomiting    O
,    O
diarrhea    O
,    O
and    O
irritable    O
bowel    O
syndrome    O
in    O
afflicted    O
individuals    O
.    O

The    O
treatments    O
for    O
significant    O
retching    O
include    O
correction    O
of    O
fluid    O
and    O
electrolyte    O
balance    O
,    O
nutritional    O
support    O
and    O
medications    O
like    O
phenothiazines    O
(    O
such    O
as    O
Compazine    O
and    O
Phenergan    O
)    O
,    O
5-HT3    O
antagonist    O
(    O
such    O
as    O
Zofran    B-Imidazole114916670
)    O
,    O
dopamine    O
receptor    O
antagonists    O
(    O
such    O
as    O
Reglan    O
)    O
,    O
antihistamines    O
(    O
Antivert    O
,    O
and    O
Dramamine    O
,    O
Benadryl    O
)    O
and    O
anticholinergics    O
(    O
Scopolamine    O
)    O
.    O

Nausea    O
and    O
vomiting    O
:    O
cisplatin    O
is    O
one    O
of    O
the    O
most    O
emetogenic    O
chemotherapy    O
agents    O
,    O
but    O
this    O
symptom    O
is    O
managed    O
with    O
prophylactic    O
antiemetics    O
(    O
ondansetron    B-Imidazole114916670
,    O
granisetron    O
,    O
etc    O
.    O
)    O
in    O
combination    O
with    O
corticosteroids    O
.    O

Aprepitant    O
combined    O
with    O
ondansetron    B-Imidazole114916670
and    O
dexamethasone    O
has    O
been    O
shown    O
to    O
be    O
better    O
for    O
highly    O
emetogenic    O
chemotherapy    O
than    O
just    O
ondansetron    B-Imidazole114916670
and    O
dexamethasone    O
.    O

It    O
should    O
not    O
be    O
confused    O
with    O
ondansetron    B-Imidazole114916670
,    O
an    O
unrelated    O
drug    O
that    O
was    O
marketed    O
in    O
South    O
Africa    O
under    O
the    O
trade    O
name    O
"    O
Dantron    O
"    O
.    O

Imiquimod    B-Imidazole114916670
acts    O
upon    O
TLR7    O
.    O

Upregulation    O
of    O
OGFr    O
and    O
consequent    O
stimulation    O
of    O
the    O
OGF    O
-    O
OGFr    O
system    O
are    O
important    O
for    O
the    O
anti    O
-    O
proliferative    O
effects    O
of    O
imidazoquinoline    O
drugs    O
like    O
imiquimod    B-Imidazole114916670
and    O
resiquimod    O
,    O
which    O
are    O
immune    O
response    O
modifiers    O
with    O
potent    O
antiviral    O
and    O
antitumour    O
effects    O
,    O
used    O
as    O
topical    O
creams    O
for    O
the    O
treatment    O
of    O
skin    O
cancers    O
and    O
warts    O
.    O

Localized    O
cutaneous    O
disease    O
can    O
be    O
treated    O
with    O
cryotherapy    O
,    O
intralesional    O
injections    O
of    O
vinblastine    O
,    O
alitretinoin    O
gel    O
,    O
radiotherapy    O
,    O
topical    O
immunotherapy    O
(    O
Imiquimod    B-Imidazole114916670
)    O
,    O
or    O
surgical    O
excision    O
.    O

The    O
core    O
structure    O
is    O
1"H    O
"-    O
imidazo[4,5-c]quinoline    O
,    O
as    O
found    O
in    O
related    O
drugs    O
such    O
as    O
imiquimod    B-Imidazole114916670
and    O
resiquimod    O
.    O

Imiquimod    B-Imidazole114916670

Benznidazole    B-Imidazole114916670

benzonidazole    B-Imidazole114916670

There    O
are    O
no    O
vaccines    O
to    O
prevent    O
these    O
infections    O
so    O
drugs    O
such    O
as    O
pentamidine    O
and    O
suramin    O
,    O
benznidazole    B-Imidazole114916670
and    O
nifurtimox    O
and    O
used    O
to    O
treat    O
infections    O
.    O

They    O
include    O
direct    O
glucocorticoid    O
receptor    O
antagonists    O
such    O
as    O
mifepristone    O
and    O
synthesis    O
inhibitors    O
such    O
as    O
metyrapone    O
,    O
ketoconazole    B-Imidazole114916670
,    O
and    O
aminoglutethimide    O
.    O

Antiglucocorticoids    O
–    O
e.g.    O
,    O
mifepristone    O
,    O
ketoconazole    B-Imidazole114916670
,    O
aminoglutethimide    O

Lurasidone    O
is    O
contraindicated    O
in    O
individuals    O
who    O
are    O
taking    O
strong    O
inhibitors    O
of    O
the    O
liver    O
enzyme    O
CYP3A4    O
(    O
ketoconazole    B-Imidazole114916670
,    O
clarithromycin    O
,    O
ritonavir    O
,    O
levodropropizine    O
,    O
etc    O
.    O
)    O
or    O
inducers    O
(    O
carbamazepine    O
,    O
St.    O
John    O
's    O
wort    O
,    O
phenytoin    O
,    O
rifampicin    O
etc    O
.    O
)    O
.    O

This    O
has    O
been    O
clinically    O
verified    O
for    O
ketoconazole    B-Imidazole114916670
,    O
which    O
increases    O
lurasidone    O
exposure    O
by    O
a    O
factor    O
of    O
9    O
,    O
and    O
is    O
also    O
expected    O
for    O
other    O
3A4    O
inhibitors    O
such    O
as    O
grapefruit    O
juice    O
.    O

Although    O
spironolactone    O
is    O
said    O
to    O
be    O
a    O
relatively    O
weak    O
inhibitor    O
of    O
17α-hydroxylase    O
and    O
17,20-lyase    O
,    O
at    O
least    O
compared    O
to    O
more    O
potent    O
steroidogenesis    O
inhibitors    O
like    O
ketoconazole    B-Imidazole114916670
and    O
abiraterone    O
acetate    O
(    O
which    O
are    O
able    O
to    O
reduce    O
testosterone    O
concentrations    O
to    O
castrate    O
levels    O
)    O
,    O
this    O
action    O
is    O
considered    O
to    O
contribute    O
a    O
significant    O
portion    O
of    O
the    O
antiandrogen    O
effects    O
of    O
spironolactone    O
,    O
for    O
instance    O
lowering    O
testosterone    O
levels    O
in    O
women    O
with    O
hyperandrogenism    O
and    O
in    O
transgender    O
women    O
.    O

It    O
's    O
also    O
contraindicated    O
if    O
patient    O
is    O
taking    O
Macrolide    O
antibiotics    O
(    O
eg    O
,    O
erythromycin    O
)    O
,    O
certain    O
HIV    O
protease    O
inhibitors    O
(    O
eg    O
,    O
ritonavir    O
,    O
nelfinavir    O
,    O
indinavir    O
)    O
,    O
certain    O
azole    O
antifungals    O
(    O
eg    O
,    O
ketoconazole    B-Imidazole114916670
,    O
itraconazole    O
,    O
voriconazole    O
)    O
delavirdine    O
,    O
efavirenz    O
or    O
a    O
5-HT1    O
agonist    O
(    O
eg    O
,    O
sumatriptan    O
)    O
.    O

Taking    O
erythromycin    O
or    O
ketoconazole    B-Imidazole114916670
while    O
taking    O
fexofenadine    O
does    O
increase    O
the    O
plasma    O
levels    O
of    O
fexofenadine    O
,    O
but    O
this    O
increase    O
does    O
not    O
influence    O
the    O
QT    O
interval    O
.    O

Inhibitors    O
of    O
the    O
liver    O
enzyme    O
CYP3A4    O
,    O
such    O
as    O
ketoconazole    B-Imidazole114916670
and    O
possibly    O
grapefruit    O
juice    O
,    O
increase    O
blood    O
plasma    O
levels    O
of    O
ticagrelor    O
and    O
consequently    O
can    O
lead    O
to    O
bleeding    O
and    O
other    O
adverse    O
effects    O
.    O

Cimetidine    O
,    O
omeprazole    O
,    O
oxcarbazepine    O
,    O
ticlopidine    O
,    O
topiramate    O
,    O
ketoconazole    B-Imidazole114916670
,    O
itraconazole    O
,    O
disulfiram    O
,    O
fluvoxamine    O
,    O
isoniazid    O
,    O
erythromycin    O
,    O
probenecid    O
,    O
propranolol    O
,    O
imipramine    O
,    O
ciprofloxacin    O
,    O
fluoxetine    O
,    O
and    O
valproic    O
acid    O
prolong    O
the    O
action    O
of    O
diazepam    O
by    O
inhibiting    O
its    O
elimination    O
.    O

Drugs    O
that    O
depend    O
on    O
stomach    O
pH    O
for    O
absorption    O
may    O
interact    O
with    O
omeprazole    O
;    O
drugs    O
that    O
depend    O
on    O
an    O
acidic    O
environment    O
(    O
such    O
as    O
ketoconazole    B-Imidazole114916670
or    O
atazanavir    O
)    O
will    O
be    O
poorly    O
absorbed    O
,    O
whereas    O
drugs    O
that    O
are    O
broken    O
down    O
in    O
acidic    O
environments    O
(    O
such    O
as    O
erythromycin    O
)    O
will    O
be    O
absorbed    O
to    O
a    O
greater    O
extent    O
than    O
normal    O
.    O

Ketoconazole    B-Imidazole114916670
,    O
itraconazole    O
,    O
ciprofloxacin    O
should    O
be    O
administered    O
at    O
a    O
different    O
time    O
from    O
didanosine    O
due    O
to    O
interactions    O
with    O
the    O
buffering    O
agent    O
.    O

Nizoral    O
(    O
against    O
dandruff    O
,    O
Active    O
substance    O
:    O
ketoconazole    B-Imidazole114916670
)    O

Nizoral    O
(    O
ketoconazole    B-Imidazole114916670
)    O
(    O
Removed    O
in    O
2005    O
)    O

Ketoconazole    B-Imidazole114916670
is    O
an    O
older    O
CYP17A1    O
inhibitor    O
that    O
is    O
now    O
little    O
used    O
.    O

The    O
metabolism    O
of    O
NOMAC    O
is    O
dependent    O
on    O
CYP3A4    O
,    O
so    O
inhibitors    O
and    O
inducers    O
of    O
this    O
enzyme    O
such    O
as    O
ketoconazole    B-Imidazole114916670
and    O
rifampicin    O
,    O
respectively    O
,    O
as    O
well    O
as    O
some    O
anticonvulsants    O
,    O
may    O
pose    O
a    O
clinically    O
significant    O
drug    O
interaction    O
with    O
NOMAC    O
.    O

In    O
the    O
case    O
of    O
a    O
household    O
dog    O
suffering    O
from    O
claudication    O
in    O
the    O
jaw    O
,    O
rigorous    O
treatment    O
with    O
ketoconazole    B-Imidazole114916670
and    O
itraconazole    O
(    O
for    O
3    O
total    O
times    O
per    O
day    O
over    O
3    O
months    O
)    O
had    O
no    O
effect    O
,    O
since    O
this    O
fungus    O
is    O
resistant    O
to    O
such    O
treatments    O
.    O

"    O
Coniochaeta    O
hoffmannii    O
"    O
has    O
proven    O
to    O
be    O
resistant    O
to    O
multiple    O
antifungal    O
agents    O
,    O
including    O
amphotericin    O
B    O
,    O
flucytosine    O
,    O
ketoconazole    B-Imidazole114916670
,    O
and    O
fluconazole    O
.    O
Because    O
of    O
this    O
,    O
precautions    O
have    O
been    O
taken    O
,    O
such    O
as    O
antifungal    O
susceptibility    O
testing    O
,    O
in    O
order    O
to    O
circumvent    O
such    O
drawbacks    O
.    O

Additionally    O
,    O
the    O
metabolism    O
of    O
zonisamide    O
is    O
inhibited    O
by    O
ketoconazole    B-Imidazole114916670
,    O
ciclosporin    O
,    O
miconazole    O
,    O
fluconazole    O
and    O
carbamazepine    O
(    O
in    O
descending    O
order    O
of    O
inhibition    O
)    O
due    O
to    O
their    O
effects    O
on    O
the    O
CYP3A4    O
enzyme    O
.    O

Antifungal    O
treatments    O
include    O
topical    O
agents    O
such    O
as    O
miconazole    O
,    O
terbinafine    O
,    O
clotrimazole    B-Imidazole114916670
,    O
ketoconazole    B-Imidazole114916670
,    O
or    O
tolnaftate    O
applied    O
twice    O
daily    O
until    O
symptoms    O
resolve    O
—    O
usually    O
within    O
one    O
or    O
two    O
weeks    O
.    O

Ketoconazole    B-Imidazole114916670

ketoconazole    B-Imidazole114916670
(    O
antifungal    O
)    O

α-Methylhistamine    B-Imidazole114916670

Penicillium    O
paneum    O
"    O
produces    O
1-Octen-3-ol    O
and    O
penipanoid    O
A    O
,    O
penipanoid    O
B    O
,    O
penipanoid    O
C    O
,    O
patulin    O
and    O
roquefortine    B-Imidazole114916670
C    I-Imidazole114916670

Roquefortine    B-Imidazole114916670
C    I-Imidazole114916670
is    O
a    O
mycotoxin    O
that    O
belongs    O
to    O
a    O
class    O
of    O
naturally    O
occurring    O
2,5-diketopiperazines    O
produced    O
by    O
various    O
fungi    O
,    O
particularly    O
species    O
from    O
the    O
"    O
Penicillium    O
"    O
genus    O
.    O

Penicillium    O
persicinum    O
"    O
produces    O
griseofulvin    O
,    O
lichexanthone    O
,    O
roquefortine    B-Imidazole114916670
C    I-Imidazole114916670
,    O
roquefortine    O
D    O
,    O
patulin    O
and    O
chrysogine    O

Etomidate    B-Imidazole114916670

Propoxate    O
(    O
INN    O
;    O
R7464    O
)    O
is    O
an    O
anesthetic    O
related    O
to    O
etomidate    B-Imidazole114916670
and    O
metomidate    B-Imidazole114916670
that    O
was    O
never    O
marketed    O
.    O

Etomidate    B-Imidazole114916670

Commonly    O
used    O
hypnotics    O
include    O
thiopental    O
,    O
propofol    O
and    O
etomidate    B-Imidazole114916670
.    O

Etomidate    B-Imidazole114916670

Immethridine    B-Imidazole114916670
is    O
a    O
histamine    O
agonist    O
selective    O
for    O
the    O
H3    O
subtype    O
.    O

Mivazerol    B-Imidazole114916670

Plinabulin    B-Imidazole114916670
(    O
chemical    B-Imidazole114916670
structure,    I-Imidazole114916670
BPI-2358,    I-Imidazole114916670
formerly    I-Imidazole114916670
NPI-2358    I-Imidazole114916670
)    O
is    O
a    O
small    O
molecule    O
under    O
development    O
by    O
BeyondSpring    O
Pharmaceuticals    O
,    O
and    O
is    O
in    O
a    O
world    O
-    O
wide    O
Phase    O
3    O
clinical    O
trial    O
for    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
.    O

Alosetron    B-Imidazole114916670
,    O
a    O
selective    O
5-HT3    O
antagonist    O
for    O
IBS    O
-    O
D    O
and    O
cilansetron    B-Imidazole114916670
(    O
also    O
a    O
selective    O
5-HT3    O
antagonist    O
)    O
were    O
trialed    O
for    O
IBS    O
.    O

Other    O
drugs    O
have    O
since    O
been    O
approved    O
,    O
among    O
them    O
notably    O
ledipasvir    B-Imidazole114916670
,    O
which    O
,    O
along    O
with    O
sofosbuvir    O
comprise    O
the    O
HCV    O
drug    O
Harvoni    O
.    O

Daclatasvir    O
was    O
developed    O
by    O
Bristol    O
-    O
Myers    O
Squibb    O
,    O
ledipasvir    B-Imidazole114916670
by    O
Gilead    O
Sciences    O
,    O
ombitasvir    O
by    O
AbbVie    O
Inc.    O
and    O

In    O
2011    O
,    O
several    O
compounds    O
(    O
antifungals    O
,    O
fungicides    O
,    O
and    O
biocides    O
)    O
where    O
shown    O
to    O
effectively    O
inhibit    O
the    O
growth    O
of    O
"    O
P.    O
destructans    O
"    O
including    O
benzalkonium    O
chloride    O
,    O
chloroacetoxyquinoline    O
,    O
chloroxine    O
,    O
ciclopirox    O
olamine    O
,    O
econazole    B-Imidazole114916670
,    O
phenylmercuric    O
acetate    O
,    O
pyrithione    O
zinc    O
and    O
sulconazole    O
.    O

econazole    B-Imidazole114916670
(    O
INN    O
)    O

Eligard    B-Imidazole114916670
(    O
Sanofi    O
-    O
Aventis    O
)    O
redirects    O
to    O
"    O
leuprolide    B-Imidazole114916670
"    O

analogues    O
include    O
agonists    O
like    O
leuprorelin    B-Imidazole114916670
or    O
goserelin    O
and    O
antagonists    O
like    O
cetrorelix    O
.    O

A    O
Phase    O
III    O
,    O
randomised    O
,    O
12    O
month    O
clinical    O
trial    O
(    O
CS21    O
)    O
in    O
prostate    O
cancer    O
compared    O
androgen    O
deprivation    O
with    O
one    O
of    O
two    O
doses    O
of    O
degarelix    O
or    O
the    O
GnRH    O
agonist    O
,    O
leuprolide    B-Imidazole114916670
.    O

Part    O
B    O
coverage    O
includes    O
chiropractic    O
care    O
,    O
out    O
patient    O
physician    O
services    O
,    O
visiting    O
nurse    O
,    O
and    O
other    O
services    O
such    O
as    O
x    O
-    O
rays    O
,    O
laboratory    O
and    O
diagnostic    O
tests    O
,    O
influenza    O
and    O
pneumonia    O
vaccinations    O
,    O
blood    O
transfusions    O
,    O
renal    O
dialysis    O
,    O
outpatient    O
hospital    O
procedures    O
,    O
limited    O
ambulance    O
transportation    O
,    O
immunosuppressive    O
drugs    O
for    O
organ    O
transplant    O
recipients    O
,    O
chemotherapy    O
,    O
hormonal    O
treatments    O
such    O
as    O
Lupron    B-Imidazole114916670
,    O
and    O
other    O
outpatient    O
medical    O
treatments    O
administered    O
in    O
a    O
doctor    O
's    O
office    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    B-Imidazole114916670
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

TAP    O
Pharmaceuticals    O
was    O
formed    O
in    O
1977    O
as    O
a    O
joint    O
venture    O
between    O
the    O
two    O
global    O
pharmaceutical    O
companies    O
,    O
Abbott    O
Laboratories    O
and    O
Takeda    O
Pharmaceutical    O
Co.    O
and    O
was    O
dissolved    O
in    O
2008    O
;    O
its    O
two    O
most    O
successful    O
products    O
were    O
proton    O
-    O
pump    O
inhibitor    O
lansoprazole    O
(    O
Prevacid    O
)    O
and    O
the    O
prostate    O
cancer    O
drug    O
,    O
leuprorelin    B-Imidazole114916670
(    O
(    O
Lupron    O
)    O
.    O

In    O
2001    O
,    O
the    O
US    O
Department    O
of    O
Justice    O
,    O
states    O
attorneys    O
general    O
,    O
and    O
TAP    O
Pharmaceutical    O
Products    O
settled    O
criminal    O
and    O
civil    O
charges    O
against    O
TAP    O
related    O
to    O
federal    O
and    O
state    O
medicare    O
fraud    O
and    O
illegal    O
marketing    O
of    O
the    O
drug    O
leuprorelin    B-Imidazole114916670
.    O

a    O
commercially    O
available    O
drug    O
delivery    O
device    O
using    O
PLGA    O
is    O
Lupron    B-Imidazole114916670
Depot    O
for    O
the    O
treatment    O
of    O
advanced    O
prostate    O
cancer    O
.    O


